In This Section

Program

Please Note: All session times for the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment are U.S. Eastern Daylight Time (EST).

Monday, November 9, 2020

Tuesday, November 10, 2020

Monday, November 9, 2020

Welcome and Educational Session
Introduction by Douglas A. Levine, NYU Langone Health, New York, New York, C. Blake Gilks, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada, Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
10-11:30 a.m.

Management of newly diagnosed endometrial cancers and molecular classification
Douglas A. Levine

Histopathology classification of endometrial cancers and surrogate markers of genomic subtypes
Blake Gilks

Navigating the complex world of adjuvant treatments and clinical trials
Victoria Bae-Jump

Break
11:30-11:45 a.m.
Plenary Session 1: Targeted Therapeutics
Session Chair: Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
11:45 a.m.-1:30 p.m.        

Challenges for future adjuvant studies and the role of immunotherapy in endometrial cancer
Remi A. Nout, Leiden University Medical Center, Leiden, Netherlands

DNA damaging agents in endometrial cancer
Shannon Neville Westin, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Endocrine therapy and ER/PR combinations
Helen J. MacKay, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Preclinical development of SHetA2 for endometrial cancer therapy*
Doris M. Benbrook, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Break
1:30-1:45 p.m.
Plenary Session 2: Functional Genomics and Proteomics
Session Chair: Russell R. Broaddus, University of North Carolina School of Medicine, Chapel Hill, North Carolina
1:45-3:45 p.m.                              

The mutational landscape of normal human endometrial epithelium
Luiza Moore, Wellcome Trust Sanger Institute, Cambridge, England

Mismatch repair deficiency and survival in stage I endometrial cancer
Russell R. Broaddus

Proteogenomic characterization of endometrial carcinoma
David Fenyo, NYU Langone Health, New York, New York

Global proteomic profiling of endometrial carcinomas identify prognostic markers*
Dawn R. Cochrane, BC Cancer Research Centre, Vancouver, BC, Canada

Multi-tissue transcriptome-wide association study identifies genetic mechanisms underlying endometrial cancer susceptibility*
Tracy M. O’Mara, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

Break
3:45-4 p.m.
Plenary Session 3: Immunotherapy
Session Chair: Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, New York
4-5 p.m.                      

Immunology of endometrial cancers: Tumor genetics, immune recognition, and immunotherapy response
Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, New York

Coordinated T and B cell responses exert immune pressure against malignant progression 
Jose R. Conejo-Garcia, Moffitt Cancer Center, Tampa, Florida

Tuesday, November 10, 2020

Keynote
Introduction by Douglas A. Levine, NYU Langone Health, New York, New York
10-10:45 a.m.

Recent progress with PTEN
Ramon Parsons, Icahn School of Medicine at Mount Sinai, New York, New York

Break
10:45-11 a.m.
Plenary Session 4: DNA Repair and Replication
Session Chair: Tjalling Bosse, Leiden University Medical Center, Leiden, Netherlands
11 a.m.-12:30 p.m.

Endometrial carcinomas with a mutation in DNA polymerase epsilon: A pathologist view
Tjalling Bosse

POLE mutations in endometrial cancer: Consequences and mechanisms
Polina V. Shcherbakova, University of Nebraska Medical Center, Omaha, Nebraska

Multi-dimensional biomarker analyses identify pembrolizumab responders in advanced stage, high grade endometrial Cancer*    
Katherine C. Fuh, Washington University School of Medicine, St. Louis, MO

CD73 sequestering mutant β-catenin at the membrane explains recurrence in CTNNB1 mutant endometrial cancer*
Jessica L. Bowser, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Break
12:30-12:45 p.m.
Plenary Session 5: Molecular Stratification
Session Chair: Jessica N. McAlpine, University of British Columbia, Vancouver, BC, Canada
12:45-2:45 p.m.                              

Molecular stratification: Beyond TCGA
David Church, Wellcome Centre for Human Genetics, University of Oxford, Oxford, England

Molecular Stratification: p53abnormal Endometrial Carcinoma – the low-hanging fruit
Naveena Singh, Barts Health NHS Trust, London, England

Molecular classification and stratification – diving deeper​
Jessica N. McAlpine

Correlation of immunohistochemistry with TP53 sequence and clinical outcomes in GOG-086P*
Kimberly K. Leslie, University of Iowa, Iowa City, Iowa

Genomic characterization of endometrial cancer patient-derived xenografts reveals intratumor heterogeneity* 
Olga Kondrashova, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

Break
2:45-3 p.m.                        
Plenary Session 6: Novel Model Systems
Session Chair: Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
3-5 p.m.                      

Breaking the obesity-endometrial cancer link: Lessons from preclinical studies
Stephen D. Hursting, University of North Carolina Chapel Hill, Chapel Hill, North Carolina

Organoids to model endometrial carcinoma subtypes
David G. Huntsman, British Columbia Cancer Research Center, Vancouver, BC, Canada

Chromatin regulation of the endometrium: What are our models telling us?
Ronald L. Chandler, Michigan State University, East Lansing, Michigan

Identifying mechanisms of immune evasion in microsatellite instable endometrial cancer mouse models*
Brenda Melendez, The University of Texas MD Anderson Cancer Center, Houston, Texas

Characterization of patient-derived xenograft models of endometrial cancer*
Kristina W. Thiel, University of Iowa, Iowa City, Iowa

*Short talk from proffered abstract

Closing Remarks
5 p.m.